Detection of Soluble ED A+ Fibronectin and Evaluation as Novel Serum Biomarker for Cardiac Tissue Remodeling
Background and Aims. Fibronectin containing the extra domain A (ED A+ Fn) was proven to serve as a valuable biomarker for cardiac remodeling. The study was aimed at establishing an ELISA to determine ED A+ Fn in serum of heart failure patients. Methods. ED A+ Fn was quantified in serum samples from 114 heart failure patients due to ischemic (ICM, n 44) and dilated (DCM, n 39) cardiomyopathy as well as hypertensive heart disease (HHD, n 31) compared to healthy controls (n 12) Results. In comparison to healthy volunteers, heart failure patients showed significantly increased levels of ED A+ Fn (p 0.001) In particular in ICM patients there were significant associations between ED A+ Fn serum levels and clinical parameters, for example, increased levels with rising NYHA class (p 0.013) a negative correlation with left ventricular ejection fraction (p 0.026, r: 0.353) a positive correlation with left atrial diameter (p 0.008, r: 0.431) and a strong positive correlation with systolic pulmonary artery pressure (p 0.002, r: 0.485) In multivariate analysis, ED A+ Fn was identified as an independent predictor of an ischemic heart failure etiology. Conclusions. The current study could clearly show that ED A+ Fn is a promising biomarker in cardiovascular diseases, especially in heart failure patients due to an ICM. We presented a valid ELISA method, which could be applied for further studies investigating the value of ED A+ Fn.
Disease markers